Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC
The TAR-200 treatment has demonstrated a favorable safety profile in clinical trial, with primarily low-grade irritated voiding symptoms that are manageable and expected with intravesical therapy, without concerning systemic side effects, making it a promising new option to delay or reduce radical cystectomy in patients with BCG-unresponsive NMIBC.
EP: 1.An Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC
EP: 3.Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC
EP: 4.Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC
EP: 5.Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
EP: 6.Other Key Trials in the Treatment of BCG-Unresponsive High-Risk NMIBC
EP: 7.Clinical Pearls for Oncologists Treating Patients With BCG-Unresponsive NMIBC
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
